INVESTORS & MEDIA
Corporate Governance
Corporate Governance
| Date | Name | Title | Type | Shares Traded | Price |
|---|---|---|---|---|---|
| Nov 30, 2011 |
Director, EVP CSO President Regeneron Re
Trans History: 576
|
Director, EVP CSO President Regeneron Re | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 196,430 | -- |
| Dec 13, 2017 |
Director, President & CSO
Trans History: 576
|
Director, President & CSO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,438 | $21.92 |
| Dec 13, 2017 |
Director, President & CSO
Trans History: 576
|
Director, President & CSO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,438 | -- |
| Dec 17, 2007 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 576
|
Director, EVP, CSO, & Pres Regn Res Labs | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 195,438 | -- |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
Trans History: 576
|
Director, President Regeneron Laboratori | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | $20.32 |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
Trans History: 576
|
Director, President Regeneron Laboratori | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | -- |
| Dec 18, 2006 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 576
|
Director, EVP, CSO, & Pres Regn Res Labs | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 195,079 | -- |
| Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 576
|
Director, EVP, CSO, & Pres Regn Res Labs | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 194,854 | -- |
| May 06, 2013 |
Director, President Regeneron Laboratori
Trans History: 576
|
Director, President Regeneron Laboratori | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 192,308 | $13.00 |
| May 06, 2013 |
Director, President Regeneron Laboratori
Trans History: 576
|
Director, President Regeneron Laboratori | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 192,308 | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.